How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

593 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Anti-Androgenic Effects of Spearmint Tea (Mentha Spicata)

as excessive hair growth in females in a male pattern, for example excess hair growth on the jaw, neck, chest or back. Other clinical manifestations of elevated androgens include alopecia, acne and ovulatory and menstrual irregularities. Spearmint tea has been shown to lower androgenic hormones in rats prompting the more recent studies involving humans. If spearmint tea is effective in treating hirsutism and elevated androgens it may have the potential to become a first-line, low risk, non-pharmaceutical (...) Anti-Androgenic Effects of Spearmint Tea (Mentha Spicata) "Anti-Androgenic Effects of Spearmint Tea (Mentha Spicata)" by Rayna Donnelly < > > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Females with elevated androgens can suffer from hirsutism, the most common clinical manifestation of hyperandrogenemia. Hirsutism affects 5 to 10% of females and is defined

2017 Pacific University EBM Capstone Project

42. Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer

Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2017 Clinical Trials

43. Destruction of the arrector pili muscle and fat infiltration in androgenic alopecia. (PubMed)

Destruction of the arrector pili muscle and fat infiltration in androgenic alopecia. Androgenic alopecia (AGA) is the most common hair loss condition in men and women. Hair loss is caused by follicle miniaturization, which is largely irreversible beyond a certain degree of follicular regression. In contrast, hair loss in telogen effluvium (TE) is readily reversible. The arrector pili muscle (APM) connects the follicle to the surrounding skin.To compare histopathological features of the APM

2014 British Journal of Dermatology

44. "Cold" X5 HairlaserTM used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study. (PubMed)

"Cold" X5 HairlaserTM used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study. Various trials have been conducted on the management and treatment of androgenic alopecia (AGA) or male pattern hair loss using a variety of laser and light sources.For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood (...) X5 hairlaser device for treating male androgenic alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value < 0.0001). Subsequent, linear regression of mean hair counts at each time point was performed, and post-hoc analysis found an increasing trend of hair growth over time that was statistically significant (p-value < 0.0001) with the estimated slope of 1.406. Increased hair counts from the baseline

Full Text available with Trip Pro

2014 BMC research notes

45. An epidemiological study of androgenic alopecia in 3114 Korean patients. (PubMed)

An epidemiological study of androgenic alopecia in 3114 Korean patients. Androgenetic alopecia (AGA) is the most common type of hair loss, and is characterized by the transformation of terminal scalp hair into vellus hair. The epidemiology of AGA is not fully understood. A strong genetic basis has long been identified, although little is known of its nongenetic causes.To evaluate the association of AGA with a number of environmental factors, including smoking, drinking and sleeping habit.In

2014 Clinical & Experimental Dermatology

46. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. (PubMed)

Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. To describe the prevalence of androgenic alopecia (AGA) in patients with polycystic ovary syndrome (PCOS) and to characterize associated clinical and biochemical features.Cross-sectional study.Multidisciplinary PCOS clinic at a tertiary academic center.A total of 254 women with PCOS according to the Rotterdam criteria were systematically examined

2014 Fertility and Sterility

47. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. (PubMed)

A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Finasteride, a selective inhibitor of type 2 5-α reductase isoenzyme, inhibits the conversion of testosterone to dihydrotestosterone (DHT) and is indicated in the treatment of male androgenetic alopecia. The study objective was to evaluate a newly developed finasteride 0.25% topical solution in comparison to the marketed finasteride 1 mg tablet (...) , with respect to finasteride pharmacokinetics and suppressive effects on plasma DHT.24 healthy men with androgenetic alopecia were randomized in a single center, open-label, parallel-group, exploratory study, and received either multiple scalp applications of the topical solution b.i.d. or oral doses of the reference tablet o.d. for 7 days. Plasma finasteride, testosterone and DHT concentrations were determined.After multiple doses, mean (± SD) finasteride C(max) and AUC(0-t) corresponded to 0.46 ± 0.28 ng

2014 International journal of clinical pharmacology and therapeutics

48. A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

49. A Meta-analysis On Evidence Of Platelet-rich Plasma for Androgenetic Alopecia. (PubMed)

] 6.38-22.38, P < 0.001). Similarly, a significantly increased hair thickness cross-section per 10-4 mm2 (MD 0.22, 95% CI 0.07-0.38, P = 0.005) favoring PRP group. The pooled results did not show a significant percentage increase in hair number (MD 18.79%, 95% CI - 8.50-46.08, P = 0.18), neither hair thickness (MD 32.63%, 95% CI - 16.23-81.48, P = 0.19) among patients treated with PRP.Local injection of PRP for androgenic alopecia might be associated with an increased number of hairs in the treated (...) A Meta-analysis On Evidence Of Platelet-rich Plasma for Androgenetic Alopecia. Platelet-rich plasma (PRP) treatment has gained popularity among different surgical specialities for improving various conditions. Androgenetic alopecia (AGA) is a common disorder, with possible psychosocial implications. Plastic surgeons have increased the practice of PRP injections for hair restoration. A meta-analysis on this topic was performed comparing local injection of PRP versus control to investigate

Full Text available with Trip Pro

2018 International journal of trichology

50. Nanofat Grafting for Treatment of Androgenetic Alopecia

provided by (Responsible Party): Hongwei Liu, Jinan University Guangzhou Study Details Study Description Go to Brief Summary: Nowadays, multiple treatment modalities have been applied clinically to treat androgenic alopecia, such as Follicular unit transplantation(FUT), finasteride, platelet-rich plasma injection(PRP), etc. In this clinical trial, the investigators aim to analyze the effect of nanofat grafting on treating androgenic alopecia in male. Condition or disease Intervention/treatment Phase (...) Androgenic Alopecia Procedure: Nanofat grafting Not Applicable Detailed Description: The investigators will treat the hair loss area of a patient by processed nanofat grafting. The participants were asked to come back 1、3、6、9、12 months after treatment for further follow-up. Before and after the treatment, the hair and follicular will be assessed subjectively by satisfaction assessment, dermatoscope. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial

2018 Clinical Trials

51. Androgenetic Alopecia and the JAK-STAT Pathway

will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand. Outcome Measures Go to Primary Outcome Measures : Different in STAT3 [ Time Frame: 6 months ] STAT3 levels in androgen-dependant areas compared to non-involved areas from occipital scalp(in an attempt to assess the possible role of the JAK-STAT pathway in androgenetic alopecia (...) Androgenetic Alopecia and the JAK-STAT Pathway Androgenetic Alopecia and the JAK-STAT Pathway - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Androgenetic Alopecia and the JAK-STAT Pathway The safety

2018 Clinical Trials

52. The Effect of Platelet Rich Plasma on Non-scarring Alopecia

an informed consent form Must be female between the ages of 18 and 65 years at the time of consent Must be able to adhere to the study visit schedule and other protocol requirements Documented platelet count above 150,000 platelets per microliter within 6 months prior to enrollment Exclusion Criteria: Previous or current use in the last 1 year of finasteride, minoxidil topical or oral, or spironolactone A diagnosis of non-androgenic alopecia (i.e: another diagnosis for the alopecia ) No Baseline ferritin (...) The Effect of Platelet Rich Plasma on Non-scarring Alopecia The Effect of Platelet Rich Plasma on Non-scarring Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Effect of Platelet Rich Plasma

2018 Clinical Trials

53. The new paradigm for androgenetic alopecia and plant-based folk remedies: 5α-Reductase inhibition, reversal of secondary microinflammation and improving insulin resistance. (PubMed)

The new paradigm for androgenetic alopecia and plant-based folk remedies: 5α-Reductase inhibition, reversal of secondary microinflammation and improving insulin resistance. Research in the past half a century has gradually sketched the biological mechanism leading to androgenetic alopecia (AGA). Until recently the aetiological paradigm has been too limited to enable intelligent commentary on the use of folk remedies to treat or reduce the expression of this condition. However, our understanding (...) is now at a point where we can describe how some folk remedies work, predict how effective they will be or why they fail.The new paradigm of AGA is that inheritance and androgens (dihydrotestosterone) are the primary contributors and a secondary pathology, microinflammation, reinforces the process at more advanced stages of follicular miniaturisation. The main protagonist to microinflammation is believed to be microbial or Demodex over-colonisation of the infundibulum of the pilosebaceous unit, which

2018 Journal of Ethnopharmacology

54. Evaluating Platelet-Rich Therapy for Facial Aesthetics and Alopecia: A Critical Review of the Literature. (PubMed)

Evaluating Platelet-Rich Therapy for Facial Aesthetics and Alopecia: A Critical Review of the Literature. Despite the growing popularity of platelet-rich plasma, existing evidence supporting its efficacy remains controversial due to the lack of large-scale studies and standardized protocols for preparation and application. This article reviews its use in facial rejuvenation, fat grafting, acne scarring, and androgenic alopecia. Emphasis is placed on comparing methods of platelet-rich plasma (...) preparation and application across studies.A systematic review was performed for articles published between 2006 and 2015. All clinical studies and case reports that addressed platelet-rich plasma alone and/or in combination with fat grafting for facial rejuvenation, acne scarring, or androgenic alopecia were included.Of the 22 articles included in the analysis, seven studies used platelet-rich plasma alone for facial rejuvenation, seven in combination with fat grafting, two for treatment of acne scarring

2018 Plastic and reconstructive surgery

55. Alopecia, androgenetic - female

Alopecia, androgenetic - female Alopecia, androgenetic - female - NICE CKS Clinical Knowledge Summaries Share Alopecia, androgenetic - female: Summary Androgenetic alopecia (or female pattern hair loss) describes a distinctive pattern of hair loss, which may occur in genetically predisposed women and is thought to be androgen dependent. Hair loss is usually diffuse and affects the top of the scalp. The underlying pathological process involves pigmented terminal hairs gradually being replaced (...) to the appropriate specialist should be considered if the woman has: An atypical presentation or extensive hair loss. Clinical or biochemical evidence of androgen excess. Adverse psychosocial effects. No response to available treatments in primary care. Have I got the right topic? Have I got the right topic? From age 18 years onwards (Female). This CKS topic covers the diagnosis and management of androgenetic alopecia for adult women in primary care. There are separate CKS topics on and . The target audience

2016 NICE Clinical Knowledge Summaries

56. Alopecia, androgenetic - male

Alopecia, androgenetic - male Alopecia, androgenetic - male - NICE CKS Clinical Knowledge Summaries Share Alopecia, androgenetic - male: Summary Androgenetic alopecia describes a distinctive pattern of hair loss, which may occur in genetically predisposed men and is thought to be androgen dependent. In men, hair loss usually initially involves the front and sides of the scalp and progresses towards the back of the head. The underlying pathological process involves pigmented terminal hairs (...) gradually being replaced by smaller, less pigmented hairs similar to vellus hairs. Male androgenetic alopecia is thought to be a polygenic disorder. It is thought that in genetically predisposed hair follicles there are increased numbers of androgen receptors and/or increased activity of 5-alpha reductase, an enzyme which mediates the effects of androgens on scalp hair. The prevalence and the severity of androgenetic alopecia is highest in white men, tends to occur less in black men, and later and more

2016 NICE Clinical Knowledge Summaries

57. Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. (PubMed)

Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. Androgen deprivation therapy (ADT) has been a mainstay of treatment for advanced prostate cancer (PCa), but limited studies have been performed to investigate the association between ADT and autoimmune diseases.We conducted a population-based nationwide cohort study of 17,168 patients newly diagnosed with PCa between 1996 and 2013 using the National Health Insurance Research Database (NHIRD) of Taiwan. Cox (...) , dermatomyositis, Hashimoto's thyroiditis, hypersensitivity vasculitis, Behcet's disease, polymyositis, alopecia areata, Wegener's granulomatosis, ulcerative colitis, autoimmune hemolytic anemia, pemphigus, multiple sclerosis, systemic sclerosis, Goodpasture syndrome, giant cell arteritis, thromboangitis obliterans, arteritis obliterans, and Kawasaki disease. The duration of ADT use as a time-dependent variable was also examined for its association with autoimmune diseases. We also performed six secondary

2019 Prostate cancer and prostatic diseases

58. Higher plasma leptin is associated with higher risk of androgenetic alopecia in men. (PubMed)

Higher plasma leptin is associated with higher risk of androgenetic alopecia in men. In addition to genetics and androgens, novel factors could play a role in androgenetic alopecia (AGA). This study aims to investigate the association between plasma leptin level with the risk and severity of AGA in men. Forty-eight subjects were enrolled including 29 AGA and 19 non-AGA subjects. The plasma leptin level was significantly higher in AGA subjects, compared to non-AGA subjects (4.45 vs 2.76 ng/mL, P

Full Text available with Trip Pro

2017 Experimental Dermatology

59. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. (PubMed)

Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. Androgenic treatment of female-to-male transgender patients may result in androgenetic alopecia (AGA). Use of 5-alpha-reductase inhibitors are useful as oral treatment of AA in men. There are no previous studies of the use of finasteride in transgender men as treatment of AGA.To evaluate the effectiveness and safety of an oral 5α-reductase inhibitor (finasteride) for AA developed (...) in transgender men.This single-centre retrospective study enrolled female-to-male transgender patients with a clinical diagnosis of AGA to receive 1 mg of an oral type II 5α-reductase inhibitor for at least 12 months.In all, 10 patients were included in the study. All the patients received a clinical diagnosis of male-pattern AGA, with 90% classified as stage IV on the Norwood-Hamilton scale. Mean onset of AGA was 3.25 years after the introduction of androgenic treatment, and 70% of the patients had a family

2017 Clinical & Experimental Dermatology

60. Adipocyte-myofibroblast transition as a possible pathophysiological step in androgenetic alopecia. (PubMed)

Adipocyte-myofibroblast transition as a possible pathophysiological step in androgenetic alopecia. Appearance of local fibrotic structures around and beneath hair follicles during their involution is a known hallmark of androgenetic alopecia (AGA). We hypothesise that this fibrosis can be connected with recently uncovered adipocyte-myofibroblast transition (AMT) involving the dermal adipocytes. This reflects that AMT is at least partially androgen-dependent, and we propose that AMT may play

Full Text available with Trip Pro

2017 Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>